Maraviroc to Augment Rehabilitation Outcomes After Stroke

NCT03172026 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Poor recruitment for each site, partly related to Covid epidemic.

Conditions

Stroke

Interventions

DRUG: Maraviroc 300 mg
BEHAVIORAL: Rehabilitation therapy
DRUG: Placebo 300 mg

Sponsor

University of California, Los Angeles